Fig. 2: Duration of response and survival. | Nature Communications

Fig. 2: Duration of response and survival.

From: Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial

Fig. 2

a Swimmer plot of patients enrolled in the trial. Each row represents a patient and the length of each bar represents the time from treatment initiation. b Kaplan-Meier survival curve for progression free survival. c Kaplan-Meier survival curve for overall survival. The cross marks on the Kaplan-Meier curves depict the censored data. Source data are provided as a Source Data file. CR complete response, OS overall survival, PFS progression-free survival, PR partial response, SD stable disease, PD progressive disease, NE not evaluable.

Back to article page